Tres Uramigas shared a post on X:
“Reviewing the highlights of ASCO25
AMPLITUDE marks a before and after in CPHSm HRR+. Niraparib + Abiraterone improves:
rPFS (HR 0.63)
Time to symptomatic progression (HR 0.50)
Trend in SG (HR 0.79)
Possible new standard in 1L?
In the BRCA1/2 subgroup:
rPFS (HR 0.52)
Time to symptomatic progression (HR 0.44)
SG (HR 0.75)
Most common G3-4 AEs: anemia (29 %) and hypertension (26 %). Low discontinuation rates due to toxicity (11 %).
You can listen to Gert Attard analyzing this data from ASCO 2025 along with Tom Powles and Brian Rini below.”
More posts featuring Tres Uramigas.
